Lattice-tip Versus Irrigated-tip Catheter for Linear Ablation of the Cavotricuspid Isthmus. A Multicenter, Randomized Study.

NCT ID: NCT07078760

Last Updated: 2025-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-16

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The LINEAR study is designed to compare the procedural efficacy, efficiency and safety of linear radiofrequency ablation of the cavotricuspid istmus using either a standar irrigated-tip ablation catheter or lattice-tip ablation catheter .The primary focus of the acute procedural data analysis will be:

Procedural efficacy: This will be evaluated based on the rate of bidirectional CTI block persistence after 60 min waiting period documented by high resolution activation mapping. Furthermore, provocative test with intravenous adenosine infusion will be conducted to exclude dormant CTI conduction.

Procedural efficiency: This will be evaluated based on the number of RF lesions delivered, time to achieve bidirectional CTI block, and fluoroscopy exposure time.

Procedural safety: The incidence of procedural complications will be recorded.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multicenter, randomized controlled trial designed to compare the efficacy, efficiency and safety of CTI catheter ablation using two different catheter technologies: the lattice-tip, dual-energy catheter (Sphere-9, Medtronic) and the irrigated radiofrequency (RF) catheter (ThermoCool® SmartTouch™, Biosense Webster, USA). The primary focus of the acute procedural data analysis will be:

Procedural efficacy: This will be evaluated based on the rate of bidirectional CTI block persistence after 60 min waiting period documented by high resolution activation mapping. Furthermore, provocative test with intravenous adenosine infusion will be conducted to exclude dormant CTI conduction.

Procedural efficiency: This will be evaluated based on the number of RF lesions delivered, time to achieve bidirectional CTI block, and fluoroscopy exposure time.

Procedural safety: The incidence of procedural complications will be recorded.

Patient Population Based on previously published data, the proportion of patients with documented CTI bidirectional block at 60 minutes as assessed by high density electroanatomical mapping is estimated at 60% for the control group. Based on preliminary studies conducted by our group, we expected a respective percentage of bidirectional block of 85% in the intervention group. Hence, for a superiority design with two-sided α of 0.05, equal (1:1) allocation between groups and 80% power, 48 patients per group (96 in total) were estimated as the target sample size. As the outcome is assessed intraprocedurally, no dropouts are expected, and therefore no further adjustments were made to the sample size estimations.

Patients will be prospectively randomized in a 1:1 ratio to one of two treatment groups:

* Group A: Patients undergoing CTI catheter ablation using RF energy delivered by the lattice-tip, dual-energy catheter (Sphere-9, Medtronic).
* Group B: Patients undergoing CTI catheter ablation using RF energy delivered by the irrigated RF catheter (ThermoCool® SmartTouch™, Biosense Webster, USA).

Ablation Procedure All participants will receive anticoagulation therapy for a minimum of one month prior to the ablation procedure. All anti-arrhythmic drugs (AADs) will be discontinued at least five half-lives before the procedure. General anesthesia (GA) will be utilized in both groups.

A decapolar electrode catheter will be positioned in the coronary sinus (CS) before the commencement of ablation. In patients presenting with sinus rhythm, ablation will be performed during pacing from the proximal CS bipole at a cycle length of approximately 600 ms. For patients presenting with typical atrial flutter, pacing will be initiated following termination of the flutter.

CTI ablation will be performed using a point-by-point catheter technique, creating a contiguous line of lesions along the CTI, guided by fluoroscopy, electroanatomical mapping. The catheter will be gently dragged from the tricuspid valve annulus towards the inferior vena cava. Intracardiac echocardiography (ICE) will be utilized as an adjunct in cases where bidirectional block is not readily achieved, to further evaluate potential anatomical variations.

In Group A, only RF energy will be delivered using the dual-energy focal 9 mm lattice-tip catheter (Sphere-9; Medtronic) according to the recommended settings. Pulsed field ablation will not be employed in this group.

In Group B, the VISITAG module will be utilized to tag the location of each RF lesion application, with the following settings: stability range of 2-3 mm, stability duration of 3-5 s, force over time of 25%, and a tag size diameter of 3 mm. The power setting will be at 30 W with a target contact force of 10-30 g and a target Ablation Index value of 400. Saline irrigation will be administered at a rate of 30 mL/min, and the temperature limit will be set at 43 °C.

Primary Efficacy Endpoint The primary procedural endpoint for efficacy will be the achievement of bidirectional CTI block. After completion of the CTI line, bidirectional block will be confirmed through differential pacing maneuvers followed by activation mapping, performed using the Affera mapping system for Group A and the CARTO mapping system for Group B, respectively. Activation mapping will be repeated 60 minutes after the initial documentation of bidirectional block to assess for its persistence or the presence of spontaneous recovery of CTI conduction

Primary Safety Endpoint The incidence of procedural complications will be recorded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Catheter Ablation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CTI radiofrequency ablation with lattice-tip catheter

Patients undergoing CTI catheter ablation using RF energy delivered by the lattice-tip, dual-energy catheter (Sphere-9, Medtronic).

Group Type ACTIVE_COMPARATOR

CTI radiofrequency ablation.

Intervention Type PROCEDURE

Cavotricuspid Isthmus ablation

CTI radiofrequency ablation performed with irrigated-tip catheter

Patients undergoing CTI catheter ablation using RF energy delivered by the irrigated RF catheter (ThermoCool® SmartTouch™, Biosense Webster, USA).

Group Type ACTIVE_COMPARATOR

CTI radiofrequency ablation.

Intervention Type PROCEDURE

Cavotricuspid Isthmus ablation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTI radiofrequency ablation.

Cavotricuspid Isthmus ablation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients above 18 years of age undergoing CTI ablation

Exclusion Criteria

* Prior right atrium ablation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mitera Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stylianos Tzeis

MD, PhD, FEHRA, Cardiologist - Electrophysiologist

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stylianos Tzeis, MD, PhD, FEHRA

Role: PRINCIPAL_INVESTIGATOR

Mitera Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mitera General Hospital

Athens, Attikis, Greece

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Greece

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stylianos Tzeis, MD, PhD, FEHRA

Role: CONTACT

+302106869777

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stylianos Tzeis, MD, PhD, FEHRA

Role: primary

+306973798970

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

833α/ΔΣ

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.